Ocular Hypertension
📧 Sign up to get email alerts when something new happens for Ocular Hypertension.
Sign up freeTop drugs studied for this disease
-
FDA label_change · 2021-06-22FDA Approved: BRINZOLAMIDE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for brinzolamide by Sandoz Inc. to update the product labeling. The update may reflect changes to in…
-
FDA label_change · 2020-04-02FDA Approved: TRAVATAN Z — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for TRAVATAN Z (travoprost) from Novartis Pharmaceuticals Corporation, resulting in a labeling c…
-
FDA label_change · 2020-02-21FDA Approved: LATANOPROST — Supplemental Application (Bausch & Lomb Incorporated)
FDA approved a supplemental application for latanoprost submitted by Bausch & Lomb Incorporated.
-
FDA label_change · 2017-09-22FDA Approved: TRAVATAN Z — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for TRAVATAN Z (travoprost) from Novartis Pharmaceuticals Corporation, resulting in updated labe…
-
FDA label_change · 2016-06-16FDA Approved: BETOPTIC S — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for BETOPTIC S (betaxolol hydrochloride) submitted by Novartis, resulting in labeling changes fo…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA label_change · 2016-03-24FDA Approved: BETOPTIC S — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Betoptic S (betaxolol hydrochloride) from Novartis, updating the drug's labeling.
-
FDA label_change · 2016-03-11FDA Approved: TRAVATAN Z — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Travatan Z (travoprost) from Novartis Pharmaceuticals Corporation. This action updates the produ…
-
FDA label_change · 2016-01-20FDA Approved: SIMBRINZA — Supplemental Application (Alcon Laboratories, Inc.)
FDA approved a supplemental application for SIMBRINZA (brinzolamide/brimonidine tartrate) submitted by Alcon Laboratories, Inc., resulting i…
-
FDA label_change · 2016-01-15FDA Approved: SIMBRINZA — Supplemental Application (Alcon Laboratories, Inc.)
The FDA approved a supplemental application for SIMBRINZA (brinzolamide/brimonidine tartrate) to update the product labeling.
-
FDA label_change · 2015-10-20FDA Approved: TIMOPTIC-XE — Supplemental Application (Bausch & Lomb Incorporated)
FDA granted a supplemental approval for TIMOPTIC-XE (timolol maleate) from Bausch & Lomb, updating the product labeling per the supplemental…
-
FDA label_change · 2015-10-06FDA Approved: TIMOLOL MALEATE — Supplemental Application (Pacific Pharma, Inc.)
FDA approved a supplemental application for timolol maleate from Pacific Pharma, Inc. to update the drug’s labeling.
-
FDA label_change · 2015-08-14FDA Approved: TIMOPTIC IN OCUDOSE — Supplemental Application (Bausch & Lomb Incorporated)
FDA approved a supplemental application for TIMOPTIC IN OCUDOSE (timolol maleate) from Bausch & Lomb Incorporated.
-
FDA label_change · 2014-12-19FDA Approved: BETAXOLOL HYDROCHLORIDE — Supplemental Application (KVK-TECH, INC.)
FDA approved a supplemental application for betaxolol hydrochloride from KVK-Tech, Inc., resulting in changes to the drug's labeling.
-
FDA label_change · 2013-02-22FDA Approved: TAFLUPROST OPHTHALMIC — Supplemental Application (Prasco Laboratories)
FDA supplemental application for Tafluprost Ophthalmic submitted by Prasco Laboratories, likely seeking changes to the product labeling. Thi…
-
FDA label_change · 2011-09-07FDA Approved: TRAVATAN Z — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for TRAVATAN Z (travoprost) submitted by Novartis Pharmaceuticals, updating the product labeling…
-
FDA label_change · 2006-06-05FDA Approved: TIMOPTIC IN OCUDOSE — Supplemental Application (Bausch & Lomb Incorporated)
This document concerns a supplemental application for Timoptic in Ocudose (timolol maleate) filed by Bausch & Lomb Incorporated.